All In Biotech

Drug Trial Radar · NCT00842673

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jun 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 168 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

168

Actual

Start

Feb 2009

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
Sonexa Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.

Conditions

  • Alzheimer's Disease

Interventions

  • ST101Drug

    30 mg; administered once/day

  • ST101Drug

    90 mg; administered once/day

  • ST101Drug

    180 mg; administered once/day

  • PlaceboDrug

    placebo to match ST101 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog)Time frame: Baseline, 4 weeks, 8 weeks,12 weeks

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Costa Mesa, California

  • Site not named

    Redlands, California

  • Site not named

    San Diego, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Durham, North Carolina

  • Site not named

    Toledo, Ohio

  • Site not named

    Jenkinton, Pennsylvania

  • Site not named

    Wichita Falls, Texas

  • Site not named

    Bennington, Vermont

  • Site not named

    Peterborough, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.